Physician profile
Sherrel E Downes
NPI 1053788828
$856.02
in general payments reported to CMS, 2019-2025
11 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $122 · 2023: $250 · 2024: $273 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.71 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $143.10 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $132.36 | 2024-2025 | Austedo Xr |
| Gilead Sciences, INC. | $116.15 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $86.82 | 2023 | Farxiga, Lokelma |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.85 | 2024 | Caplyta |
| Avanir Pharmaceuticals, INC. | $85.56 | 2021 | |
| Urovant Sciences INC | $82.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $56.23 | 2021-2022 | |
| Radius Health, INC. | $25.86 | 2023 | |
| Bausch Health US, LLC | $22.51 | 2024 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $19.55 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherrel Downes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.